PubMed · 1992 · 28 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyAntineoplastic Drug ClassesCytotoxic ChemotherapyMalignant NeoplasmsOncology PharmacologyAnticancer ActivityAnticancer ChemotherapyAntineoplastic Drug TherapyCancer Cell Proliferation InhibitionDna Synthesis InhibitionEnzymatic Dna SynthesisPurine AnaloguesPurine Biosynthesis
1-Acyl- and 1,2-diacyl-1,2,4-triazolidine-3,5-diones were found to be potent cytotoxic agents in murine and human cancer cell lines, e.g. L1210, P388, Tmolt3, colon adenocarcinoma, Hela cells and glioma. In vivo activity was demonstrated at 8 mg/kg/day against Ehrlich ascites carcinoma growth. In L1210 cells, 1-acetyl-4-phenyl-1,2,4-triazolidine-3,5-dione, 41, reduced DNA synthesis significantly with moderate reduction in RNA synthesis. Enzyme sites in L1210 cells which were markedly affected were m- and r-RNA polymerase, PRPP amidotransferase, IMP dehydrogenase, dihydrofolate reductase, thymidine, TMP and TDP kinases. Kinetic studies suggest the inhibition of rate limiting enzymes in the purine pathway by 41 was responsible for its cytotoxicity. Acute toxicity studies in mice indicated 41 was safe for therapeutic use at 20, 50, and 100 mg/ky/day.